Akums Drugs and Pharmaceuticals Limited — Investor Meet, 19-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Akums Drugs & Pharmaceuticals Limited reported strong financial results for the quarter, with operating revenue at INR 1,160 Cr (+14.8% YoY) and operating EBITDA at INR 147 Cr (+21% YoY), driven by improved margins of 12.7%. The CDMO business saw 16.3% YoY revenue growth, fueled by broad-based, sustainable double-digit volume increases. International branded formulations showed significant demand recovery. Management highlighted progress on EU CDMO (oral solid supplies commenced, liquids from FY28 with EUR 35 million annual contract) and the Zambia project (USD 25 million annual supplies from India). The injectables facility is ramping up. The company emphasizes innovation, efficiency, and strategic partnerships, actively exploring M&A opportunities.